NewsMeter
1.46 billion Swiss francs ($1.8 billion) is the all-cash figure South Korea's Samsung Biologics has placed on Switzerland's PolyPeptide Group. The offer was disclosed on Monday.
Cash only: no equity component was attached to the bid.
Deal at a glance | Item | Detail | |---|---| | Offer price | CHF 1.46 billion | | Dollar equivalent | $1.8 billion | | Structure | All-cash | | Acquirer | Samsung Biologics (South Korea) | | Target | PolyPeptide Group (Switzerland) | | Announced | Monday | The offer CHF 1.46 billion converts to $1.8 billion.
That is the full cash consideration Samsung Biologics has put on the table for PolyPeptide Group. No board recommendation from the Swiss company or closing timeline appeared in Monday's disclosure.
Keep reading